The first would involve excluding from AD cohorts those patients who suffer from clinical depression [16, 19, 20, 32, 33, 35, 43, 66] or by assessing its influence on BDNF levels [21, 45]. The gene discussed is BDNF; the disease is depressive symptom measurement.